The biotech company intends to explore ways to move ahead with developing the treatment, including seeking a new collaborator ...

Sangamo Therapeutics Inc.’s stock tumbled 56% on Tuesday for its second-biggest one-day percentage decline ever, after Pfizer ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...

Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone payments ...

PFE ends deal with SGMO for hemophilia A gene therapy candidate. NVS' gene therapy for SMA meets goal in study.

The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future ...

Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development ...

9 analysts have shared their evaluations of Sangamo Therapeutics SGMO during the recent three months, expressing a mix of ...

Sangamo (SGMO) stock faces challenges as Pfizer terminates partnership for hemophilia A gene therapy, impacting share price ...

Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.

NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...

Sangamo Therapeutics (SGMO) stock plunged as Pfizer (PFE) ends collaboration on hemophilia A gene therapy. Find out the ...